Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech : BioNTech shots have stronger antibody response than Sinovac, Hong Kong study shows - SCMP

06/19/2021 | 12:59am EDT

June 19 (Reuters) - People who are vaccinated against COVID-19 with BioNTech's vaccine were found to have "substantially higher" levels of antibodies than those who received Sinovac's jab, the South China Morning Post reported https://bit.ly/3iX7S5t on Saturday, citing a Hong Kong study.

Some who received the Sinovac vaccine might need a third booster shot as well, the newspaper said, citing lead researcher Professor Benjamin Cowling, an epidemiologist with the University of Hong Kong (HKU).

The government-commissioned study was conducted by HKU's school of public health and involved tracking the antibody responses of 1,000 people who received either vaccine, the report added.

Earlier this week, officials in Indonesia warned that more than 350 medical workers have caught COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, raising concerns about its efficacy against more infectious variants of the virus.

Earlier in June, Uruguay released real-world data on the impact of Sinovac Biotech's COVID-19 vaccine among its population that showed it was over 90% effective in preventing intensive care admissions and deaths.

The Uruguay government also studied the effectiveness of the Pfizer/BioNTech's vaccine among 162,047 health workers and people over 80 years old, and said the shot was 94% effective at preventing intensive care unit admissions and deaths, and reduced infections by 78%. (Reporting by Nandakumar D in Bengaluru; Editing by Raju Gopalakrishnan)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 5.04% 328.35 Delayed Quote.302.78%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SINOVAC BIOTECH LTD.
07/27SINOVAC BIOTECH : Antibodies from Sinovac's COVID-19 shot fade after about 6 mon..
RE
07/26SINOVAC BIOTECH : Brazil says China's Sinopharm seeks COVID-19 vaccine emergency..
RE
07/26SINOVAC BIOTECH : Antibodies from Sinovac's COVID-19 shot fade after about 6 mon..
RE
07/24SINOVAC BIOTECH : Indonesia prepares more ICU units, waits to see if COVID curbs..
RE
07/23SINOVAC BIOTECH : China's Sinovac evaluates vaccine plant in Chile
RE
07/20SINOVAC BIOTECH : Receives Approval on Sabin Strain Based Inactivated Polio Vacc..
PU
07/20SINOVAC BIOTECH : CoronaVac Used on Child Population in China, Good Antibody Lev..
PU
07/20SINOVAC Biotech Ltd. Announces Use of CoronaVac, its COVID-19 Vaccine on Chil..
CI
07/19SINOVAC BIOTECH : Polio Vaccine Gets China's Medical Regulator OK
MT
07/19SINOVAC BIOTECH : Receives Approval on Sabin Strain Based Inactivated Polio Vacc..
BU
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED2.02%96 600
WUXI BIOLOGICS (CAYMAN) INC.15.27%64 616
SAMSUNG BIOLOGICS CO.,LTD.7.75%51 119
BIOGEN INC.33.44%48 694
ALEXION PHARMACEUTICALS, INC.0.00%40 336